Sphingomyelin nanosystems decorated with TSP-1 derived peptide targeting senescent cells

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Gerontology

Background:

• Senescent cell accumulation contributes to age-related diseases and cancer.
• The 4N1Ks peptide targets senescent cells via CD47 but faces biopharmaceutical challenges.
• Sphingomyelin nanosystems (SNs) offer a potential solution for peptide drug delivery.

Purpose of the Study:

• To develop and characterize peptide-decorated sphingomyelin nanosystems (SNs-4N1Ks) for targeted senescent cell elimination.
• To evaluate the therapeutic potential of SNs-4N1Ks in cancer treatment.

Main Methods:

• Chemical conjugation of 4N1Ks peptide to PEGylated hydrophobic chains for SNs decoration.
• Physicochemical characterization of SNs-4N1Ks using DLS, MALS, NTA, and AFM.
• In vitro evaluation of cytotoxicity, colony formation, hemocompatibility, and senolytic activity in cancer cells.

Main Results:

• SNs-4N1Ks exhibited optimal size (~100 nm), high association efficiency (87.2%), and good stability.
• SNs-4N1Ks demonstrated enhanced cytotoxicity and reduced colony formation in MCF7 cancer cells compared to free peptide.
• Preliminary studies showed improved senolytic activity of SNs-4N1Ks in a chemotherapy-induced senescence model.

Conclusions:

• SNs-4N1Ks represent a promising nanocarrier system for the 4N1Ks peptide, enhancing its senolytic efficacy.
• This approach offers a novel strategy for developing innovative senolytic therapies against cancer.
• Further research into SNs-4N1Ks could lead to effective treatments for age-related diseases.